$NRXP

NRX Pharmaceuticals, Inc. (NRXP) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 NRx Pharmaceuticals (Nasdaq:NRXP) Receives FDA Approval of Preservative-Free Ketamine Ahead of November 10 FDA Goal Date October 30, 2026 ● Preservative-Free Ketamine is an American-manufactured presentation of ketamine that contains no benzethonium chloride (BZT), a

NRx Pharmaceuticals (NRXP) announced FDA approval for its preservative-free ketamine injection, ahead of the November 10 goal date. The product lacks benzethonium chloride, a toxic preservative in current ketamine injections. NRx aims to address the ketamine shortage and reshored manufacturing to the U.S. with Nephron Pharmaceuticals. The company will host a conference call on October 30 to discuss the approval.

NRx Pharmaceuticals (NRXP) completed manufacturing validation for preservative-free ketamine, meeting FDA GMP standards. Stability data suggests a potential 3-year shelf life. The drug is ready for commercial release pending FDA approval of its ANDA. NRX-100, for suicidal ideation, has FDA Fast Track Designation.

NRx Pharmaceuticals scheduled its 2026 Annual Meeting for December 17, 2026, as a virtual-only event. The company set October 25-26, 2026 as deadlines for stockholder proposals and director nominations. The record date for voting is October 28, 2026, according to the company.

NRx Pharmaceuticals (NRXP) received a 'DISCIPLINE REVIEW LETTER' from the FDA requesting minor label changes for its preservative-free ketamine product. The company must submit sample labeling with the proposed proprietary name by the November 10, 2026 GDUFA goal date. NRx is completing final manufacturing validation runs for product launch compliance. The company aims to address ketamine shortages in the U.S. and believes its preservative-free version is important for patients.

NRX Pharmaceuticals, via subsidiary NRx Defense Systems, secured an $11.2M contract with DARPA for an 18-month SPARC-TMS trial in treatment-resistant depression. The deal includes $6.7M initially obligated, with payments tied to milestones. The FDA-approved trial is set to begin patient enrollment. According to the SEC filing, the contract advances the SPARC-TMS trial.

NRX Pharmaceuticals, Inc. (NRXP) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Exhibit 99.1 NRx Defense Systems, an NRx Company (Nasdaq:NRXP) Awarded $11 Million Dollar DARPA Prime Contract to Evaluate Robotic Magnetic Stimulation in conjunction with NRX-101 for Treatment of Resistant Depression September 30, 2026 07:00 ET | Source: NRx Pharmaceuticals, Inc

NRx Defense Systems, a subsidiary of NRx Pharmaceuticals (NRXP), received an $11.18M DARPA contract to evaluate robotic magnetic stimulation with NRX-101 for treating resistant depression. The SPARC-TMS trial, led by Harvard, ASU, and others, aims to replicate 91% response rates from prior studies. Success could support FDA approval for NRX-101 in this indication.

NRx Pharmaceuticals (NRXP) received an earlier FDA goal date of Nov. 10 for its preservative-free ketamine application after the FDA reclassified a filing amendment from major to minor, reducing review resources. The company aims to address a drug shortage with this product, according to its CEO.

NRx Pharmaceuticals (NRXP) reported that the FDA reclassified its ANDA amendment for preservative-free ketamine from a Major to a Minor Amendment, revising the GDUFA goal date to November 10, 2026. The company expressed appreciation for the FDA's expedited process.